text:
Home » Celebrities » 'GMA' Anchor Amy Robach 'Almost' Finalizes Divorce From Andrew Shue Amid T.J. Holmes Affair
'GMA' Anchor Amy Robach 'Almost' Finalizes Divorce From Andrew Shue Amid T.J. Holmes Affair
One source reveals that Amy and T.J. are indeed dating, saying, 'They're in a relationship, they're very happy' as 'they are both broken up from their spouses.'
AceShowbiz –Amy Robach is going to be legally single soon. After news about her affair with T.J. Holmes made media headlines, a new report suggests that the "Good Morning America" anchor "almost" finalizes her divorce from her husband Andrew Shue.
"Amy and Andrew are divorcing, it's almost finalized," one friend informed Page Six on Thursday, December 1. "He moved out earlier this summer. They've constantly had problems over the years and they finally broke up."
Another source then told the outlet that Amy and T.J. are indeed dating. "They're in a relationship, they're very happy. They are both broken up from their spouses and they're two consenting adults – they have the right to do what they want," the informant said.
One TV insider, meanwhile, claimed that it wouldn't be surprising if Amy had any romantic flings during her marriage to Andrew. "It wouldn't surprise me. She and Andrew had their rocky moments – they almost broke up a few times over the years. But it's not like Amy is some serial philanderer," the insider explained.
Amy and Andrew got married in 2010, two years after her divorce from Tim McIntosh. Amy herself shares two teenage daughters with Tim.
Amy has hinted at her split from Andrew by removing her wedding band and stopping posting photos of her spouse. The 49-year-old eventually deactivated her account on Wednesday afternoon, November 30 after fans noticed it.
T.J.'s Instagram account has also been deactivated, although Page Six notes that he made the move before his relationship with Amy made headlines.
Multiple reports suggested Amy and T.J.'s steamy relationship began in March when they started training together for the New York City Half Marathon, which Amy ran with Andrew. They have been since spotted getting affectionate on many occasions, both in indoor and outdoor settings.
Chris Brown Unhappy With Joe Biden Amid Talks About Tax Increase
Brian Austin Green Throwing Subs at Megan Fox Amid Machine Gun Kelly Hookup Rumors
Adele, Mary J. Blige & Miranda Lambert Among Time's 100 Most Influential People Of 2022
Why Prince Harry and Meghan Markle started 'afresh' with one another
Paul Gascoigne shares special bond with Dancing On Ice star son Regan over OCD diagnosis
« First Guardians of the Galaxy Vol. 3 Trailer Teases Emotional End to Trilogy
Mena Suvari Reveals Ongoing Battle With Postpartum Depression: 'I Was Going Crazy'' »
How Shakira Responded To Gerard Piqué Going IG Official With His Mistress!
Katharine McPhee and David Foster Not in Any Crazy Rush to Add Another Baby


text:
Flavin-Containing Monooxygenase-Mediated Metabolism ofN-Deacetyl Ketoconazole by Rat Hepatic Microsomes
Rosita J. Rodriguez, Philip J. Proteau, Brian L. Marquez, Craig L. Hetherington, Cheryl J. Buckholz and Kerry L. O'Connell
Drug Metabolism and Disposition August 1999, 27 (8) 880-886;
Rosita J. Rodriguez
Philip J. Proteau
Brian L. Marquez
Craig L. Hetherington
Cheryl J. Buckholz
Kerry L. O'Connell
Although ketoconazole is extensively metabolized by hepatic microsomal enzymes, the route of formation and toxicity of suspected metabolites are largely unknown. Reports indicate thatN-deacetyl ketoconazole (DAK) is a major initial metabolite in mice. DAK may be susceptible to successive oxidative attacks on the N-1 position by flavin-containing monooxygenases (FMO) producing potentially toxic metabolites. Previous laboratory findings have demonstrated that postnatal rat hepatic microsomes metabolize DAK by NADPH-dependent monooxygenases to two metabolites as determined by HPLC. Our current investigation evaluated DAK's metabolism in adult male and female rats and identified metabolites that may be responsible for ketoconazole's hepatotoxicity. DAK was extensively metabolized by rat liver microsomal monooxygenases at pH 8.8 in pyrophosphate buffer containing the glucose 6-phosphate NADPH-generating system to three metabolites as determined by HPLC. The initial metabolite of DAK was a secondary hydroxylamine,N-deacetyl-N-hydroxyketoconazole, which was confirmed by liquid chromatography/mass spectrometry and NMR spectroscopy. Extensive metabolism of DAK occurred at pH 8.8 in pyrophosphate buffer (female 29% and male 53% at 0.25 h; female 55% and male 57% at 0.5 h; and female 62% and male 66% at 1.0 h). Significantly less metabolism of DAK occurred at pH 7.4 in phosphate buffer (female 11%, male 17% at 0.25 h; female 20%, male 31% at 0.5 h; and female 27%, male 37% at 1 h). Heat inactivation of microsomal-FMO abolished the formation of these metabolites from DAK. SKF-525A did not inhibit this reaction. These results suggest that DAK appears to be extensively metabolized by adult FMO-mediated monooxygenation.
Ketoconazole (KT)1 and other azoles (fluconazole and itraconazole) are prominent broad-spectrum oral antifungal agents used in the treatment of systemic mycoses, especially in patients who are susceptible to opportunistic systemic fungal infections (Ringel, 1990). KT and related azoles exert their antifungal actions by inhibiting lanosterol 14α-demethylase which is responsible for the conversion of lanosterol to ergosterol in fungi (Van Den Bossche et al., 1980). KT has been shown to have similar inhibitory effects on mammalian cytochrome P-450 (CYP) enzymes responsible for the conversion of lanosterol to cholesterol, a major component of membranes in mammals (Strandberg et al., 1987). In addition to its antimycotic activity, an inhibitory effect on the synthesis of testosterone in both testicular and adrenal cells makes KT a suitable candidate for treatment of androgen-dependent diseases such as advanced prostate cancer (Pont et al., 1984; Jubelirer and Hogan, 1989; Vogelzang and Kennealey, 1992). Also, KT has been shown to be a strong selective in vitro inhibitor of CYP3A (Maurice et al., 1992).
KT has been reported to be extensively metabolized to a large number of metabolites, with hepatic-microsomal enzymes playing the major role in the biotransformation reactions (Gascoigne et al., 1981;Daneshmend and Warnock, 1988). The metabolic pathways suggested include CYP-mediated oxidation, cleavage, degradation and scission of the imidazole and piperazine rings, oxidative O-dealkylation, and aromatic hydroxylation (Heel et al., 1982; Daneshmend and Warnock, 1988). The major metabolite in mice, deacetyl ketoconazole (DAK), Fig. 1, accumulates to significant levels in hepatic tissues, whereas accumulation of KT in the mouse liver is minimal (Whitehouse et al., 1994a,b). Moreover, two N-oxide metabolites of KT have been isolated from mouse liver (Whitehouse et al., 1994a). The formation of the aforementioned metabolites could be CYP- or flavin-containing monooxygenase (FMO)-mediated.
Proposed metabolic pathway ofDAK by the FMO to reactive metabolites.
Numbering of ketoconazole is based on Whitehouse et al. (1994a).
Due to KT's extensive therapeutic usage, there have been numerous documented cases of KT-induced hepatotoxicity (Bercoff et al., 1985;Benson et al., 1988; Brusko and Marten, 1991). Rechallenge of KT in patients resulted in enhanced toxicity (Van Parys et al., 1987). The biochemical features related to KT hepatotoxicity generally tend to be hepatocellular injury in 57% of the patients and cholestatic injury in 43% of the patients (Stricker et al., 1986). Many reports indicate that the type of hepatic injury is zone 3 necrosis (Stricker et al., 1986; Benson et al., 1988). The overall incidence of clinical hepatitis appears to be on the order of 0.01 to 0.1% of the patients and many cases appear to be subclinical (Stricker et al., 1986). The actual incidence is probably greater due to underreporting (Stricker et al., 1986; Knight et al., 1991). The hepatotoxicity was usually reversible when the drug was discontinued but recovery usually took as long as 3 to 6 months (Janssen and Symoens, 1983; Benson et al., 1988). Apoptosis through the p53-dependent pathway may be a mechanism by which KT induces toxicity in cultured rat liver cells (Ho et al., 1998).
Because the clinical literature has clearly demonstrated that KT can be toxic to the liver resulting in serious adverse reactions, new azole derivatives have been developed for antimycotic activity and for the treatment of prostate cancer. The newer azole derivatives, fluconazole and itraconazole are now being used extensively along with KT. Similarly to KT, there have been reports of fatal hepatic necrosis related to fluconazole (Bodey, 1992; Jacobson et al., 1994) and a dose-dependent/rechallenge of fluconazole-induced hepatotoxicity (Wells and Lever, 1992). Furthermore, itraconazole has been reported to cause drug-induced hepatitis (Lavrijsen et al., 1992; Hann et al., 1993). Our previous studies have demonstrated that KT's primary metabolite,DAK, may be responsible, in part, for the hepatotoxicity associated with KT (Rodriguez and Acosta, 1997b). As previously mentioned, DAK appears to be the major metabolite formed and accumulated in the liver of mice. This deacetylated metabolite may then be susceptible to further metabolism. We propose that bioactivation ofDAK through successive oxidative attacks by FMO on the piperazine ring may generate secondary, then primary hydroxylamines, as shown in Fig. 1. These hydroxylamines, or their further metabolites, such as a ring-opened dialdehyde, could result in toxic consequences that produces hepatic injury. Metabolism of KT by FMO may have been overlooked because the initial literature indicated that KT's metabolism appeared to be CYP-mediated and the role of FMO in drug metabolism was relatively less understood. To date, none of our proposed metabolites in the metabolism of DAK by FMO have been reported in the literature; thus, our objective was to evaluate, isolate, and identify DAK's metabolites apparently generated by FMO using rat hepatic microsomes.
Chemicals.
All chemicals were obtained from Sigma Chemical Co. (St. Louis, MO) unless otherwise stated. DAK was a generous gift from Janssen Pharmaceutica (Beerse, Belgium). Solvents used for HPLC analysis were HPLC grade. NMR solvents were obtained from Cambridge Isotope Laboratories (Andover, MA).
Isolation of Rat Liver Microsomes.
The liver tissues were removed from male and female Sprague-Dawley rats (180–200 g) and immediately placed on ice. The tissues were homogenized with 0.25 M sucrose, 100 mM Tris, and 1 mM EDTA, pH 7.5. Microsomes were prepared by standard differential centrifugation and stored in 10 mM Tris, 1 mM EDTA, and 20% glycerol, pH 7.5. The samples were frozen in liquid nitrogen and stored at −80°C. Protein was determined using the Coomassie Plus Assay from Pierce (Rockford, IL).
Metabolic Assays.
In vitro metabolism of DAK by microsomes from rat liver was a modified procedure of Miranda et al. (1991). The incubation mixture consisted of 1.5 mg microsomal protein, 100 mM glycine/25 mM pyrophosphate buffer, pH 8.8, 100 μM DAK, 3 mM octylamine, and the NADPH-generating system (10 mM glucose 6-phosphate, 1.0 U/ml glucose 6-phosphate dehydrogenase and 1 mM NADP+) in a total volume of 0.5 ml. After a 0.25-, 0.5-, and 1-h incubation at 37°C with shaking, the reaction was terminated with 0.5 ml of ice-cold methanol with 0.5%, v/v, formic acid and cooled on ice. Proteins were precipitated by centrifugation at 14,000g for 15 min at 4°C and aliquots of the supernatant were analyzed by HPLC as described above. Microsomal-FMO activity was inhibited by heat-inactivation to determine the effect of heat treatment on FMO activity (Ziegler, 1980). The microsomes were heated at 50°C for 90 s before adding them to the incubation mixture. To evaluate CYP metabolism of DAK, the microsomes were added to an incubation mixture consisting of 100 mM phosphate buffer, pH 7.4, 100 μM DAK, and the NADPH-generating system. In addition to evaluating CYP metabolism, 0.5 mM SKF-525A was added to the microsomal incubation mixture consisting of 1.5 mg of microsomal protein, 100 mM glycine-25 mM pyrophosphate buffer, pH 8.8, 100 μM DAK,and the NADPH-generating system.
HPLC.
HPLC analysis for DAK and its metabolites was performed with a Waters system (Milford, MA) that consisted of a Waters C18 symmetry column connected to a Waters Alliance 2690 Solvent Delivery System, Waters 996 photodiode array detector, Waters 2690 autosampler and Millennium Chromatography software version 3.0.DAK and its metabolites were eluted with 0.005 M ammonium formate (pH 4.5) and 20 to 60% acetonitrile at a flow rate of 1.0 ml/min, with UV detection at 220 nm.
Isolation of Metabolites by HPLC.
Metabolites were isolated from the 1-h incubation of DAK and the microsomal sample incubation. The supernatant was concentrated by removing the organic solvent (methanol) in a Savant Speed Vac Plus (Farmingdale, NY) connected to a refrigerated vapor trap. The sample was then injected onto the HPLC column. Fractions were collected for each peak of interest. These fractions were dried in the Speed Vac, redissolved in acetonitrile, and reinjected onto the HPLC for further purification. Individual metabolites were again collected, dried, and stored under nitrogen gas at −20°C until structural characterization studies could be performed.
NMR.
NMR spectra were recorded on a Bruker DRX600 spectrometer (Billerica, MA) in acetonitrile-d3. NMR spectra were referenced to CHD2CN at 1.94. The major metabolite sample (∼100 μg) was dissolved in 40 μl of solvent, then transferred to a Shigemi, Inc. microtube (Allison Park, PA) for accumulation of data. DAK and the model compound samples were prepared in standard 5-mm NMR tubes in ∼0.4 ml of solvent.
Liquid Chromatography/Mass Spectrometry (LC/MS).
Three microliters of a concentrated 1-h incubation sample was injected onto a chromatography system consisting of a Perkin Elmer ABI 140 B syringe pump, a Rheodyne 8125 injector with a 5-μl sample loop, and a 3-mm × 150-mm, 5-μm particle Waters C18 symmetry column. The solvents were 0.005 M ammonium formate (pH 4.5) and acetonitrile, which were delivered at 400 μl/min and programmed from 20% acetonitrile to 60% acetonitrile in 30 min. The individual HPLC peaks were directly analyzed with a Perkin Elmer Sciex API III + triple quadruple ion spray mass spectrometer (Ontario, Canada) using an atmospheric pressure chemical ionization source. Assignments are based on those of Whitehouse et al. (1994a) and through the use of heteronuclear single quantum coherence experiments.
All data represent a minimum of three separate experiments with triplicate determinations and were expressed as the mean ± standard error (S.E.) unless otherwise indicated. The statistical significance of the difference of mean values of treated and control groups was evaluated by a one-way completely randomized factor ANOVA with significance set at p < .05.
Figure 2 is a representative HPLC chromatogram of DAK's metabolism after a 1-h incubation period of DAK and the hepatic microsomes in the NADPH-generating system, at pH 8.8. The retention times forDAK and its metabolites were: DAK, 7.45 min; metabolite 1, 7.85 min; metabolite 2 (major), 8.70 min; and metabolite 3, 9.32 min. Metabolite 2 (M2) was the predominant metabolite peak formed at all time points evaluated from both the male and female hepatic microsomal incubations, whereas there was minimal formation of metabolites 1 (M1) and 3 (M3; Fig.3). Figure 3 demonstrates the disappearance of DAK and the formation of its metabolites from male rat hepatic microsomes over the 1-h incubation period. The female rat hepatic microsomes displayed the same metabolic profile (data not shown). However, the male microsomes extensively metabolizedDAK (53%) at 0.25 h when compared with the female microsomes (29%). At 0.5 h and 1 h, there were no significant differences (p > .05) between the male and female (male 57%, female 55% at 0.5 h and male 66%, female 62% at 1 h). The metabolites of interest were characterized by LC/MS and 1H NMR spectrometry. The results of the LC/MS indicated the molecular weights ofDAK (mw 489), M1 (mw 503), M2 (mw 505), and M3 (mw 517); data not shown. Table1 shows the 1H NMR spectrum of DAK and M2.
High performance liquid chromatogram ofDAK's metabolism in a NADPH-generating system, pH 8.8.
Retention times: DAK, 7.45 min; M1, 7.85 min;M2, 8.70 min; and M3, 9.32 min.
Metabolite formation from DAKin male rat hepatic microsomes as determined by HPLC peak area.
DAK, ▪; M1, ●; M2, ▴; andM3, ♦. Error bars represent S.E.M. of three experiments performed in triplicate.
1H NMR data for DAK and M2(N-hydroxy DAK)
The results of DAK's metabolism from the various male hepatic-microsomal incubations are presented in Fig.4. There was no metabolism ofDAK from the microsomal incubation that did not contain the NADPH-generating system. Heat inactivation of FMO, which will abolish FMO activity while preserving CYP activity (Ziegler, 1980), completely inhibited the metabolism of DAK. The female rat hepatic microsomes displayed the same metabolic profile (data not shown). No significant differences were seen between the heat-inactivated FMO incubation and the incubation without the NADPH-generating system for both the male and female hepatic microsomes (p> .05). Extensive metabolism occurred by 1 h (>60%) with the male and female hepatic microsomes with the FMO pyrophosphate buffer system containing the NADPH-generating system with SKF-525A, an inhibitor of CYP (male 39%, female 27% at 0.25 h; male 66%, female 56% at 0.5 h; and male 66%, female 65% at 1 h). There were no significant differences (p > .05) between the FMO pyrophosphate buffer system with and without SKF-525A for the male and female microsomes at all time points except for the 0.25-h male hepatic microsomes (p < .05). Thus, the metabolism of DAK was not significantly altered with the addition of SKF-525A. In contrast, significantly less metabolism of DAK occurred in the CYP phosphate buffer, pH 7.4 (male 17%, female 11% at 0.25h; male 31%, female 20% at 0.5 h; and male 37%, female 27% at 1 h). There was statistical significance (p < .05) with the male and female hepatic microsomes at all time points for the CYP phosphate buffer system compared with the FMO pyrophosphate buffer system.
Percentage of DAKremaining in the hepatic microsomal incubation from male rats after various treatments.
No NADPH-generating system, ▪; NADPH-generating system, ●; heat inactivation of FMO, 50°C, ♦; SKF-525A and the NADPH-generating system, ▴; and phosphate buffer and the NADPH-generating system, pH 7.4, ▾. Error bars represent S.E.M. of three experiments performed in triplicate. Statistical significance from the NADPH-generating system, *p < .0005; **p < .05.
Figures 5 and6 show the percentages of metabolites formed after incubation with DAK from male hepatic microsomes. Results shown in Fig. 5 demonstrate that metabolism ofDAK was greater in the pyrophosphate buffer, pH 8.8 (optimum conditions for FMO metabolism) than in the CYP phosphate buffer system, pH 7.4. The female hepatic microsomes displayed similar results. In addition, M2 appeared to be the initial metabolite formed from DAK in the pyrophosphate buffer as early as 0.25 h (30%), continued to increase at 0.5 h (43%), and then began to decease by 1 h (39%). Unlike the male hepatic microsomes,M2 formation from the female hepatic microsomes in the pyrophosphate buffer increased over time to 22% at 0.25 h, 47% at 0.5 h, and 48% at 1 h. As M2 deceased over time from the male hepatic microsomes, there was an increase in metabolite formation of M1 and M3. M1began to appear as early as 0.25 h (5%) and was present at 0.5 h (14%) and at 1.0 h (12%). M3 also began to appear at 0.25 h (3%) and continued to increase over time to 8% at 0.5 h and 14% at 1 h. As for the female hepatic microsomes, M1 remained at 5% over the time period evaluated. In contrast, M3 began to increase over time to 2% at 0.25 h (2%), 6% at 0.5 h, and 9% at 1h.
The NADPH-generating system at optimum conditions for FMO pyrophosphate buffer, pH 8.8 (solid line), and CYP phosphate buffer, pH 7.4 (dashed line). DAK, ▪, ■; M1, ●, ○;M2, ▴, ▵ (piperazine 2°-hydroxylamine); andM3, ♦, ⋄). Error bars represent S.E.M. of three experiments performed in triplicate. Statistical significance ofDAK disappearance in pyrophosphate buffer, pH 8.8, *p < .0005. Statistical significance ofM2 in the pyrophosphate buffer, † p < .0005.
Metabolite formation from DAKin male rat hepatic microsomes in the presence of SKF-525A as determined by HPLC peak area.
Coincubation with SKF-525A (dashed lines) and absence of SKF-525A (solid lines). DAK, ▪, ■; M1, ●, ○;M2, ▴, ▵ (piperazine 2°-hydroxylamine); andM3, ♦, ⋄. Error bars represent S.E.M. of three experiments performed in triplicate. Statistical significance ofDAK disappearance without SKF-525A, *p< .01.
The metabolism of DAK in the CYP phosphate buffer was not as extensive as the FMO pyrophosphate buffer. M2 appeared to be the initial metabolite formed from DAK in phosphate buffer as early as 0.25 h (10%) and increased at 0.5 h (23%) and 1.0 h (24%). M2 formation from the female hepatic microsomes also increased overtime in the phosphate buffer to 5% at 0.25 h, 16% at 0.5 h, and 20% at 1 h. M1began to appear as early as 0.25 h (5%) and was present at 0.5 h (8%) and 1 h (7%) in the male hepatic-microsomal incubations. M3 also began to appear at 0.25 h (2%), and increased at 0.5 h (7%), and was still present at 1.0 h (6%). As for the female hepatic microsomes in the phosphate buffer,M1 began to appear as early as 0.25 h (9%) and was present at 0.5 h (3%) and 1.0 h (3%). M3 began to increase over time to 2% at 0.25 h, 2% at 0.5 h, and 4% at 1 h. Thus, metabolite formation was greatly reduced in the phosphate buffer compared with the pyrophosphate buffer.
In Fig. 6, the metabolism of DAK or the formation of its metabolites were not significantly altered (p> .05) with the addition of SKF-525A, a CYP inhibitor, in the male liver microsomes at 0.5 h and 1.0 h; however, there was a significant decrease in metabolism at 0.25 h (p < .01). No significance in DAKmetabolism was seen for the female microsomes at all time points evaluated (p > .05). In addition, metabolite formation was not significantly altered (p > .05) in the presence of SKF-525A. Similarly, the use of anti-rat NADPH IgG reductase to inhibit microsomal-CYP in the incubation mixture did not alter the metabolism of DAK or its metabolite formation (data not shown). Thus, the CYP inhibitors did not display any significant inhibitory effect in hepatic microsomal metabolism ofDAK. These results suggest that DAK is primarily converted to three metabolites, one of which is the piperazine secondary hydroxylamine, by FMO and not by CYP in the rat liver microsomes.
KT's primary metabolite, DAK, appears to be the major metabolite formed and accumulated in liver (Whitehouse et al., 1990). Our earlier studies demonstrated that DAK may be responsible, in part, for the hepatotoxicity associated with KT (Rodriguez and Acosta, 1997b). DAK was more cytotoxic than KT in a time- and dose-response relationship using postnatal (8- to 10-day-old) rat hepatocytes, suggesting that bioactivation ofDAK may be responsible for the observed hepatotoxicity (Rodriguez and Acosta, 1997b). Thus, the deacetylated metabolite may be susceptible to further hepatic metabolism. In addition, our findings demonstrated that postnatal rat hepatic microsomes metabolizeDAK by NADPH-dependent monooxygenases to two metabolites as determined by HPLC (Rodriguez and Acosta, 1997a). Furthermore,DAK's toxicity was enhanced with octylamine, a known positive effector for FMO as well as a CYP inhibitor (Cashman and Ziegler, 1986), and was suppressed with methimazole, a competitive substrate for FMO, thus suggesting that FMO may play a role in KT's hepatotoxicity (Rodriguez and Acosta, 1997b). We propose that bioactivation of DAK through successive oxidative attacks by FMO on the piperazine ring may generate secondary or primary hydroxylamines. These amines may also serve as substrates of FMO, eventually forming a ring-opened dialdehyde (Fig. 1). Any one or several of these metabolites, especially the aldehydes, may result in toxic consequences. Thus, increased susceptibility of liver cells toDAK may be a result of its metabolism by FMO to a toxic metabolite. FMO metabolism of KT may have been overlooked because the initial literature indicated that KT's metabolism appeared to be CYP-mediated and the role of FMO in drug metabolism was relatively less understood. To date, none of our proposed metabolites in metabolism ofDAK by FMO have been reported; however, we have now identified a DAK metabolite that is apparently generated by FMO using rat hepatic microsomes.
The major metabolite of DAK (mw 489) was determined by LC/MS analysis to have a mw of 505, which indicates an increase in mass of 16 mass units, consistent with addition of a single oxygen atom to the structure. The 1H NMR spectrum of this metabolite in acetonitrile-d3 showed only minor variations in chemical shifts for protons in the imidazole, dichlorophenyl, glycerol, and disubstituted benzene portions of the structure compared with DAK, but significant chemical shift changes were observed in the region corresponding to the piperazine ring (Table 1). The piperazine ring is therefore the site of oxidation. Three possible structures can be envisioned, the secondary hydroxylamine (A), the tertiary N-oxide (B), or a ring-hydroxylated structure (C), Fig.7. The third structure, which would likely be an equilibrium mixture of cyclic and open chain forms if stable enough to be isolated, would require seven different carbon-bound protons, with the methine proton at the site of oxidation significantly deshielded relative to the remaining protons. In the1H NMR spectrum, eight protons are observed as four two-proton signals, eliminating structure C as a possibility. The N-oxide B would be expected to show significant effects on not only the piperazine ring protons, but also the disubstituted benzene ring protons (Whitehouse et al., 1994a). The shifts for the benzene ring protons in M2 are unaltered from those of DAK (Table 1). The data support the secondary hydroxylamine (A) as the major metabolite. Further evidence for structure A was obtained by synthesizing a secondary hydroxylamine model compound (Biloski and Ganem, 1983), 1-hydroxy-4-phenylpiperazine, from 1-phenylpiperazine and recording its NMR spectra. The 1H chemical shift changes and overall patterns observed on conversion of 1-phenylpiperazine to 1-hydroxy-4-phenylpiperazine were very similar to those seen when converting DAK to its major metabolite (Table2). Furthermore, hydroxylamine formation from 1-phenylpiperazine has previously been reported in rat liver homogenates (Achari and Beckett, 1983). We therefore conclude thatM2,N-deacetyl-N-hydroxy-ketoconazole (cis-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-hydroxypiperazine; N-hydroxy-DAK), has the secondary hydroxylamine structure A.
Possible structures for oxidation of the piperazine ring: the secondary hydroxylamine (A), the tertiary N-oxide (B), or a ring-hydroxylated structure (C).
1H NMR data for phenylpiperazine model compounds
LC/MS experiments also indicated that M1 had a mw of 503, which is consistent with formation of a nitrone from M2(loss of 2 mass units). Earlier studies have shown that hepatic microsomal-FMO catalyzed the formation of nitrones from hydroxylamines (Kadlubar et al., 1973). Formation of M1 increased in a time-dependent manner after formation of N-hydroxy-DAK (Fig. 3). As the incubation time period increased, N-hydroxy-DAK decreased andM1 and M3 began to be detected by HPLC. This supports further FMO-mediated metabolism of N-hydroxy-DAK. Attempts to obtain NMR spectral data for M1 were unsuccessful, possibly due to degradation during the work-up procedure for NMR analysis and due to the limited quantity of M1.
Metabolism of DAK by male and female rat microsomes was evaluated because it has been demonstrated that male rats have higher FMO activity than female (Skett et al., 1980; Dannan et al., 1986;Lemoine et al., 1991). Disappearance of DAK from male hepatic microsomes was similar to female hepatic microsomes. However, 0.25-h male microsomal metabolism of DAK was extensive when compared with the female, 53 and 29%, respectively. By 1 h, similar extensive metabolism of DAK occurred in both male and female microsomal incubations with FMO pyrophosphate buffer system containing the NADPH-generating system with and without SKF-525A. Because extensive metabolism occurred by 0.25 h, it is possible that the end product, N-hydroxy-DAK, may have inhibited the reaction as early as 0.25 h, resulting in nonlinear kinetics. Metabolism of DAK in CYP phosphate buffer was significantly less compared with the FMO pyrophosphate buffer system. Moreover, both male and female displayed similar metabolic profiles ofDAK in CYP phosphate buffer system. Lastly, heat inactivation of microsomal FMO completely abolished N-hydroxy-DAK, M1, and M3formation. Therefore, male and female rat hepatic microsomes appear to metabolize DAK by FMO.
N-hydroxy-DAK was the predominant metabolite ofDAK formed from both male and female hepatic microsomes. N-hydroxy-DAK appeared to undergo subsequent metabolism to M1 and M3 as indicated by the decrease of N-hydroxy-DAK and an increase inM1 and M3 formation. Although M1 andM3 were formed from N-hydroxy-DAKfrom female hepatic microsomes, metabolite formation was less than the male. We speculate that gender differences between male and female rats may play a role with DAK's metabolite formation.Cherrington et al. (1998) has reported that hepatic FMO3 and FMO5 are gender-independent in rat, whereas FMO1 appears to be selective to the male rat. Thus, DAK may be a substrate for hepatic FMO1, FMO3, and FMO5, whereas N-hydroxy-DAK may be a substrate for FMO3 and FMO5. Therefore, M1 and M3 could still be generated from female hepatic microsomes but not to the same extent seen with male hepatic microsomes.
Also, metabolism of DAK was greater in the FMO pyrophosphate buffer than in the CYP phosphate buffer system for both male and female hepatic microsomes. There was no significant differences inM1 and M3 formation between the male and female in the CYP phosphate buffer system. Furthermore, DAK'smetabolism or formation of its metabolites were not significantly altered in the presence of SKF-525A, a CYP inhibitor. Similarly, use of anti-rat NADPH IgG reductase to inhibit microsomal CYP in the incubation mixture did not alter metabolism of DAK or its metabolites. Thus, these data support that metabolism of DAKis not CYP mediated.
Lastly, our earlier study with postnatal (8- to 10-day-old) rat hepatic microsomes demonstrated that DAK was a substrate for FMO (Rodriguez and Acosta, 1997a). Metabolism of DAK occurred as early as 0.25 h (29%) up to 43% at 1 h in the FMO buffer. N-hydroxy-DAK was formed as early as 0.25 h (19%) and increased to 30% by 1 h. Also, M1 andM3 began to increase over the incubation period, (M1, 9% and M3, 6% at 0.25 h;M1, 9% and M3, 7% at 0.5 h; andM1, 11% and M3, 7% at 1.0 h). As seen with the adults, minimal metabolism of DAK and formation of its metabolites occurred in the CYP phosphate buffer. DAK was metabolized by 25% at 1.0 h with metabolite formation: N-hydroxy-DAK, 10%; M1, 11%, andM3, 3% formed by 1.0 h in the CYP phosphate buffer. Postnatal rats may display similar characteristics as mice in which FMO1 and FMO5 are present in hepatic tissue, whereas FMO3 was detected 2 weeks postpartum (Cherrington et al., 1998). Thus, postnatal rat hepatic microsomes possess hepatic FMO enzymes necessary for FMO-mediated metabolism as seen with adult microsomes.
In conclusion, we propose that bioactivation of DAK through oxidation attack by FMO on the piperazine ring generates a secondary hydroxylamine, N-hydroxy-DAK, which is susceptible to further FMO-mediated oxidative attacks. These products of further FMO metabolism may lead to toxic consequences. Continued efforts are being made to identify the remaining metabolites (M1 and M3) apparently generated by FMO. Moreover, current studies with recombinant human FMO3 confirm FMO-mediated metabolism of DAK to N-hydroxy-DAK (manuscript in preparation). Other metabolites may have been formed from DAK that were not detected by the HPLC method used in the present study. Lastly, if both oxidation and reduction reactions occur rapidly, tissue NADPH concentrations may be perturbed (Ziegler, 1988). NADPH could be depleted during metabolism of DAK to N-hydroxy-DAK and M1 andM3. Loss of cellular NADPH would affect a number of cellular processes and may be responsible, in part, for toxicity. Thus, it is possible that DAK's metabolism to N-hydroxy-DAK by FMO may play a role in the hepatotoxicity associated with KT.
We thank Dr. C. L. Miranda for his helpful suggestions and Donald Griffin for his assistance with the LC/MS experiments.
Send reprint requests to: Dr. Rosita J. Rodriguez, College of Pharmacy, Oregon State University, Corvallis, OR 97331-3507. E-mail: Rosita.Rodriguez{at}orst.edu
This work was supported by Oregon State University's Research Council (to R.J.R.) and the Apprenticeship in Science and Engineering Program (to C.L.H. and K.L.O.). The Bruker DRX600 spectrometer was purchased with financial assistance from the National Science Foundation (CHE-9413692) and the Keck Foundation.
Abbreviations used are::
N-deacetyl ketoconazole
flavin-containing monooxygenases
Accepted April 16, 1999.
Achari R,
Beckett AH
(1983) In-vitro metabolism of two mono-substituted piperazines using liver homogenates of rats and rabbits. J Pharm Pharmacol 35:615–616.
Benson GD,
Anderson PK,
Combes B,
Ishak KG
(1988) Prolonged jaundice following ketoconazole-induced hepatic injury. Dig Dis Sci 33:240–246.
Bercoff E,
Bernuau J,
Degott C,
Kalis B,
Lamaire A,
Tilly H,
Rueff B,
Benhamou JP
(1985) Ketoconazole-induced fulminant hepatitis. Gut 26:636–638.
Biloski AJ and Ganem B (1983) Improved oxidation of amines with dibenzoyl peroxide. Synthesis 537–538..
Bodey GP
(1992) Azole antifungal agents. Clin Infect Dis 14(Suppl) S161–S169.
Brusko CS,
Marten JT
(1991) Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis. Ann Pharmacother 25:1321–1325.
Cashman JR,
Ziegler DM
(1986) Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine) by various liver preparations. Mol Pharmacol 29:163–167.
Cherrington NJ,
Cao Y,
Cherrington JW,
Rose RL,
Hodgson E
(1998) Physiological factors affecting protein expression of flavin-containing monooxygenases 1, 3, and 5. Xenobiotica 28:673–682.
Daneshmend TK,
Warnock DW
(1988) Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 14:13–34.
Dannan GA,
Guengerich FP,
Waxman DJ
(1986) Hormonal regulation of rat liver microsomal enzymes. J Biol Chem 261:10728–10735.
Gascoigne EW,
Barton GJ,
Michaels M,
Meuldermans W,
Heykants J
(1981) The kinetics of ketoconazole in animals and man. Clin Res Rev 1:177–187.
Hann SK,
Kim JB,
Im S,
Han KH,
Park YK
(1993) Itraconazole-induced acute hepatitis. Br J Dermatol 129:500–501.
Heel RC,
Brogden RN,
Carmine A,
Morley PA,
Speight TM,
Avery GS
(1982) Ketoconazole: A review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23:1–36.
Ho Y-S,
Tsai P-W,
Yu C-F,
Liu H-L,
Chen R-J,
Lin J-K
(1998) Ketoconazole-induced apoptosis through P53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol 153:39–47.
Jacobson MA,
Hanks DK,
Ferrell LD
(1994) Fatal acute hepatic necrosis due to fluconazole. Am J Med 96:188–190.
Janssen PA,
Symoens JE
(1983) Hepatic reactions during ketoconazole treatment. Am J Med 74:80–85.
Jubelirer SJ,
Hogan T
(1989) High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature. J Urol 142:89–91.
Kadlubar FF,
McKee EM,
(1973) Reduced pyridine nucleotide-dependent N-hydroxy amine oxidase and reductase activities of hepatic microsomes. Arch Biochem Biophys 156:46–57.
Knight TE,
Shikuma CY,
Knight J
(1991) Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 25:398–400.
Lavrijsen APM,
Balmus KJ,
Nugtern-Huying WM,
Robdaan AC,
van't Wout JW,
Stricker BHC
(1992) Hepatic injury associated with itraconazole. Lancet 340:251–252.
Lemoine A,
Williams DE,
Cresteil T,
Leroux JP
(1991) Hormonal regulation of microsomal flavin-containing monooxygenase: Tissue-dependent expression and substrate specificity. Mol Pharmacol 40:211–217.
Maurice M,
Pichard L,
Daujat M,
Fabre I,
Joyeux H,
Domergue J,
Maurel P
(1992) Effects of imidazole derivatives on cytochrome P450 from human hepatocytes in primary culture. FASEB J 6:752–758.
Miranda CL,
Chung W,
Reed RE,
Zhao X,
Henderson MC,
Wang JL,
Buhler DR
(1991) Flavin-containing monooxygenase: A major detoxifying enzyme for the pyrrolizidine alkaloid senecionine in guinea pig tissues. Biochem Biophys Res Commun 178:546–552.
Pont A,
Graybill JR,
Craven PC,
Galgiani JN,
Dismukes WE,
Reitz RE,
Stevens DA
(1984) High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 144:2150–2153.
Ringel SM
(1990) New antifungal agents for the systemic mycoses. Mycopathologia 109:77–87.
Rodriguez RJ,
Acosta D
(1997a) Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and flavin-containing monooxygenases. Drug Metab Dispos 25:772–777.
(1997b) N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 117:123–131.
Skett P,
Mode A.,
Rafter J,
Sahlin L,
Gustafsson J-A
(1980) The effects of gonadectomy and hypophysectomy on the metabolism of imipramine and lidocaine by the liver of male and female rats. Biochem Pharmacol 29:2759–2762.
Strandberg TE,
Tilvis RS,
Miettinen TA
(1987) Effects of ketoconazole on cholesterol synthesis and precursor concentrations in the rat liver. Lipids 22:1020–1024.
Stricker BHC,
Blok APR,
Bronkhorst FB,
Van Parys GE,
Desmet VJ
(1986) Ketoconazole-associated hepatic injury a clinicopathological study of 55 cases. J Hepatol 3:399–406.
Van Den Bossche H,
Willemsens G,
Cools W,
Cornelissen F,
Lauwers WF,
Van Cutsen JM
(1980) In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 17:922–928.
Van Parys G,
Evenepoel C,
Van Damme B,
(1987) Ketoconazole-induced hepatitis: A case with a definite cause-effect relationship. Liver 7:27–30.
Vogelzang NJ,
Kennealey GT
(1992) Recent development in endocrine treatment of prostate cancer. Cancer 70:966–975.
Wells C,
Lever AML
(1992) Dose dependent fluconazole hepatotoxicity proven on biopsy and rechallenge. J Infect 24:111–112.
Whitehouse LW,
Menzies A,
Dawson B,
Cyr TD,
By AW,
Black DB,
Zamecnik J
(1994a) Mouse hepatic metabolites of ketoconazole: Isolation and structure elucidation. J Pharm Biomed Anal 12:1425–1441.
Zamecnik J,
Sy WW
(1990) Deacetylated ketoconazole: a major ketoconazole metabolite isolated from mouse liver. J Pharm Biomed Anal 8:603–606.
Mueller R,
Pontefract R
(1994b) Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole. Toxicology 94:81–95.
(1980) Microsomal flavin-containing monooxygenase: Oxygenation of nucleophilic nitrogen and sulfur compounds. Enzymatic Basis of Detoxication (Academic Press, New York), 1:201–227.
(1988) Flavin-containing monooxygenases: Catalytic mechanism and substrate specificities. Drug Metabol Rev 19:1–32.
You are going to email the following Flavin-Containing Monooxygenase-Mediated Metabolism ofN-Deacetyl Ketoconazole by Rat Hepatic Microsomes
Drug Metabolism and Disposition August 1, 1999, 27 (8) 880-886;
Show more Article

redpajama_set_name: RedPajamaCommonCrawl


text:
Academic Journal Articles
Pamphlets and Working Papers
France moves into a new political space
Posted on April 23, 2017 March 26, 2019 by peadarkirby
So, the French have shown again that politics really matters and has become the space where different visions of the future are being fought out. And, while the centrist candidate, Emmanuel Macron now appears certain to be France's next president, the first round of the 2017 presidential election has already brought massive changes.
As we have seen elsewhere, voters are decisively rejecting long-established mainstream parties and giving support both to new parties and, in increasing numbers, to parties on the extreme right and left. France has now demonstrated these tendencies more strongly than has any other country.
Neither of the two parties that have dominated the politics of the 5th Republic, the centre left and the centre right, made it to the second round. Perhaps the greatest disaster was the 6% vote received by the ruling Socialist Party candidate, Benoit Hammon, but the travails of the centre right candidate, Francois Fillon, and the fact that the vote he received was similar to that of the far left candidate, Jean Luc Mélenchon, also marks a political earthquake.
Attention now turns to the clear option presented to the French in the second round of voting, the centrist vision of the relative newcomer Macron, optimistic but vague and ill-defined, and the firm right-wing, inward-looking and fearful message of Marine Le Pen. Both will face much harder questioning over the next two weeks about the sort of France they want.
Is Macron, as Paul Mason is tweeting as the results come in, the candidate of the 'global-liberal elite' or can he offer a credible project of social change that can combine elements of liberal economic policies with strong social supports? If Macron manages to do this, it has implications for centrist liberal politics throughout Europe and beyond.
Two other factors deserve mention in relation to Macron. One is that his campaign has mobilised a new social movement, En Marche. This, then, is a different form of centrist politics based not primarily on an established party but on mobilising especially young people who have been largely alienated from politics. How this movement institutionalises itself as Macron goes on to become president has potential to renew French political life.
The second factor is that Macron signals a generation change in French politics. Having someone who is 39 years of age reach the highest political office, is symbolically important in a Europe where politics remains dominated by leaders who are in their 60s or even 70s. These leaders who politicised within stable systems dominated by the Christian Democrats and Social Democrats. With Macron we have a political leader who has emerged as these systems unravel. How, or if, a new politics coalesces under his leadership will be fascinating to watch.
And then there is the Front Nacional. Though we can breathe a sigh of relief that Marine Le Pen will not make it to the Elysee, election 2017 confirms yet again that around a quarter of the French electorate continues firmly to support a party that wants to go back to an imagined past and that plays loose with our liberal democratic order. It remains a reason for profound concern.
Beyond Coronavirus: Contributions from Karl Polanyi
Covid-19 and climate change: will it help or hinder?
New development model is biggest challenge for next government
Reinventing Sinn Féin as a left-wing party
New book from Peadar Kirby
Karl Polanyi and the Contemporary Political Crisis: Transforming Market Society in the Era of Climate Change
Has politics reached breaking point? Rather than defending liberalism or abandoning it, how can a socially just and ecological alternative be built? My new book investigates the causes of our current multifaceted global crisis by drawing on the work of Karl Polanyi. This book explores Polanyi's theory that social disruptions result from the attempt to run society according to the rules of the market. Drawing on these ideas, it outlines pathways towards an alternative future that overcome weaknesses in Marxism. Linking the ecological, political and socio-economic crises, The book identifies that an alternative socio-ecological model is emerging, consistent with the insights of Polanyi. Karl Polanyi and the Contemporary Political Crisis is being published in early December 2020 and is a contribution to key debates on the future of politics, on the low-carbon transition, on automation and on the emerging world order
Categories Select Category Academic Books Blog Book Chapters Journalism Lectures Pamphlets and Working Papers Uncategorized
Lectures DCU
Lectures UL
Archives Select Month April 2020 February 2020 June 2019 April 2019 January 2019 December 2018 June 2017 April 2017 March 2017 December 2016 November 2016 June 2016 May 2016 March 2016 February 2016 January 2016 December 2015 September 2015 July 2015 March 2015 February 2015 December 2014 June 2014 January 2014 December 2010 December 2009
©2021 Peadar Kirby	| WordPress Theme by SuperbThemes


Make your dream of building your home in the Brainerd Lakes area a reality with these lots close to Breezy Point Resort.
I was searching for a Property and found this listing (MLS® #4948909). Please send me more information regarding 209 Rainer Dr, Breezy Point, MN, 56472. Thank you!
I'd like to request a showing of 209 Rainer Dr, Breezy Point, MN, 56472 (MLS® #4948909). Thank you!


text:
.. _assets:

Assets
==========

Assets can be added to SpringBoard in order to include new art for editing. They should be added in the ``springboard/assets`` folder, and each asset pack should have its own directory structure.

SpringBoard supports the following asset types:

- **Brush patterns** */brush_patterns*. These should be black images with an alpha determining the value.
- **Materials** */materials*. Materials consist of multiple different textures (``diffuse``, ``specular`` and ``normal``), which should be contained in different image files, in the ``name_$texType.png`` format, e.g. ``cement_diffuse.png`` and ``cement_specular.png``.
- **Skyboxes** */skyboxes*. These should be ``.dds`` skybox textures.
- **Detail textures** */detail*. These are the usual Spring detail textures.

A set of core assets are available. You can download them either via the launcher's ``Asset Download`` option (recommended), or manually via a `direct link <https://content.spring-launcher.com/core_v1.zip>`_. In case of a manual download, you need to extract them to ``springboard/assets/core/``.

redpajama_set_name: RedPajamaGithub